Skip to main content
Erschienen in: Medical Oncology 11/2014

01.11.2014 | Original Paper

Wild-type genotypes of BRCA1 gene SNPs combined with micro-RNA over-expression in mammary tissue leading to familial breast cancer with an increased risk of distant metastases’ occurrence

verfasst von: Imen Medimegh, Wafa Troudi, Nejla Stambouli, Houssein Khodjet-El-Khil, Olfa Baroudi, Hajer Ayari, Ines Omrane, Nancy Uhrhammer, Maud Privat, Amel Mezlini, Farhat Ben Ayed, Khaled Ben Romdhane, Sylvie Mader, Yve Jean Bignon, Amel Benammar Elgaaied

Erschienen in: Medical Oncology | Ausgabe 11/2014

Einloggen, um Zugang zu erhalten

Abstract

Germ line deleterious mutations of BRCA1 gene are not the unique factor that could inactivate BRCA1 protein which leads to familial breast cancer onset with distant metastases’ occurrence. The present research explores the role that could be assigned to BRCA1 SNPs to inactivate BRCA1 protein and therefore to the occurrence of familial breast cancer with an increased risk of distant metastases’ occurrence. The presence or the absence of BRCA1 protein was first analyzed by applying the immunohistochemistry technique to the tumors with sporadic and familial breast cancer. Then, a case–control study was conducted including 40 patients with familial breast cancer, 46 ones with sporadic breast cancer and 34 healthy controls based on the genotyping of nine BRCA1 SNPs (c.442.58delT, c.2082C>T, c.2311T>C, c.2612C>T, c.3113A>G, c.3119G>A, c.3548A>G, c.4308T>C and 4837A>G) via direct sequencing. Finally, the functional role that could be assigned to these SNPs was focused upon. miRbase site was used as a bioinformatics tool to predict potential micro-RNAs (miRs) targeting SNPs that are associated with familial breast cancer according to the results of this research. These predicted miRs were confirmed by Q-PCR analysis and correlated with BRCA1 protein expression among patients along with potential distant metastases. Clinical outcome showed that distant metastasis concerned 45 % of familial breast cancer patients and 19.5 % with sporadic breast cancer. Analysis of BRCA1 protein expression revealed a negative staining among 46.6 % of familial breast cancer patients and only 16.6 % within sporadic breast cancer ones. The association of four variants was identified within BRCA1 gene (c.442.58 delT, c.2311T>C, c.2612C>T and c.4308T>C) to familial breast cancer across their wild genotypes. miR-1179 was selected as potential miR that targets the region of BRCA1 mRNA containing the c.2311T>C variant within the TT genotype. The expression of miR-1179 was significantly associated with familial breast cancer patients without BRCA1 deleterious mutations compared to those with sporadic breast cancer according to TT genotype along with BRCA1 negative staining and according to the occurrence of distant metastases. Combination between TT genotype of c.2311T>C and miR-1179 over-expression could generate a lack of BRCA1 protein leading to a high risk of familial breast cancer with distant metastases.
Literatur
1.
Zurück zum Zitat Saika K, Sobue T. Cancer statistics in the world. Gan To Kagaku Ryoho. 2013;40(13):2475–80.PubMed Saika K, Sobue T. Cancer statistics in the world. Gan To Kagaku Ryoho. 2013;40(13):2475–80.PubMed
2.
Zurück zum Zitat Charef-Hamza S, et al. Loss of heterozygosity at the BRCA1 locus in Tunisian women with sporadic breast cancer. Cancer Lett. 2005;224(2):185–91.PubMedCrossRef Charef-Hamza S, et al. Loss of heterozygosity at the BRCA1 locus in Tunisian women with sporadic breast cancer. Cancer Lett. 2005;224(2):185–91.PubMedCrossRef
3.
Zurück zum Zitat Guaragnella N, et al. The expanding role of yeast in cancer research and diagnosis: insights into the function of the oncosuppressors p53 and BRCA1/2. FEMS Yeast Res. 2013;111(10):548–62. Guaragnella N, et al. The expanding role of yeast in cancer research and diagnosis: insights into the function of the oncosuppressors p53 and BRCA1/2. FEMS Yeast Res. 2013;111(10):548–62.
4.
Zurück zum Zitat Albiges L, et al. Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastases. Ann Oncol. 2005;16(11):1846–7.PubMedCrossRef Albiges L, et al. Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastases. Ann Oncol. 2005;16(11):1846–7.PubMedCrossRef
5.
Zurück zum Zitat Egawa C, et al. Quantitative analysis of BRCA1 and BRCA2 mRNA expression in sporadic breast carcinomas and its relationship with clinicopathological characteristics. Jpn J Cancer Res. 2001;92(6):624–30.PubMedCrossRef Egawa C, et al. Quantitative analysis of BRCA1 and BRCA2 mRNA expression in sporadic breast carcinomas and its relationship with clinicopathological characteristics. Jpn J Cancer Res. 2001;92(6):624–30.PubMedCrossRef
6.
Zurück zum Zitat Wu J, Lu LY, Yu X. The role of BRCA1 in DNA damage response. Protein Cell. 2010;1(2):117–23. Wu J, Lu LY, Yu X. The role of BRCA1 in DNA damage response. Protein Cell. 2010;1(2):117–23.
7.
Zurück zum Zitat Troudi W, et al. Contribution of the BRCA1 and BRCA2 mutations to breast cancer in Tunisia. J Hum Genet. 2007;52(11):915–20.PubMedCrossRef Troudi W, et al. Contribution of the BRCA1 and BRCA2 mutations to breast cancer in Tunisia. J Hum Genet. 2007;52(11):915–20.PubMedCrossRef
8.
Zurück zum Zitat Im KM, et al. Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. Hum Genet. 2011;130(5):685–99. Im KM, et al. Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. Hum Genet. 2011;130(5):685–99.
9.
Zurück zum Zitat Cao W, et al. BRCA1 germ-line mutations and tumor characteristics in eastern Chinese women with familial breast cancer. Anat Rec (Hoboken). 2013;296(2):273–8.CrossRef Cao W, et al. BRCA1 germ-line mutations and tumor characteristics in eastern Chinese women with familial breast cancer. Anat Rec (Hoboken). 2013;296(2):273–8.CrossRef
10.
Zurück zum Zitat Troudi W, et al. Complete mutation screening and haplotype characterization of BRCA1 gene in Tunisian patients with familial breast cancer. Cancer Biomark. 2008;4(1):11–8.PubMed Troudi W, et al. Complete mutation screening and haplotype characterization of BRCA1 gene in Tunisian patients with familial breast cancer. Cancer Biomark. 2008;4(1):11–8.PubMed
11.
Zurück zum Zitat Chang S, et al. Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155. Nat Med. 2011;17(10):1275–82. Chang S, et al. Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155. Nat Med. 2011;17(10):1275–82.
12.
Zurück zum Zitat Folini M, et al. miR-21: an oncomir on strike in prostate cancer. Mol Cancer. 2010;9:12. Folini M, et al. miR-21: an oncomir on strike in prostate cancer. Mol Cancer. 2010;9:12.
13.
Zurück zum Zitat He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5(7):522–31.PubMedCrossRef He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5(7):522–31.PubMedCrossRef
14.
Zurück zum Zitat Moskwa P, et al. miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell. 2011;41(2):210–20. Moskwa P, et al. miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell. 2011;41(2):210–20.
15.
Zurück zum Zitat Griffiths-Jones S, et al. miRBase: tools for microRNA genomics. Nucleic Acids Res. 2008;36(Database issue):D154–8. Griffiths-Jones S, et al. miRBase: tools for microRNA genomics. Nucleic Acids Res. 2008;36(Database issue):D154–8.
17.
Zurück zum Zitat Filipponi D, et al. Wip1 controls global heterochromatin silencing via atm/BRCA1-dependent dna methylation. Cancer Cell. 2013;24(4):528–41.PubMedCrossRef Filipponi D, et al. Wip1 controls global heterochromatin silencing via atm/BRCA1-dependent dna methylation. Cancer Cell. 2013;24(4):528–41.PubMedCrossRef
19.
Zurück zum Zitat McMullin RP, et al. A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity. Breast Cancer Res. 2014;16(2):R25.PubMedCrossRefPubMedCentral McMullin RP, et al. A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity. Breast Cancer Res. 2014;16(2):R25.PubMedCrossRefPubMedCentral
20.
Zurück zum Zitat Bouhaha R, et al. Study of TNFalpha-308G/A and IL6-174G/C polymorphisms in type 2 diabetes and obesity risk in the Tunisian population. Clin Biochem. 2010;43(6):549–52.PubMedCrossRef Bouhaha R, et al. Study of TNFalpha-308G/A and IL6-174G/C polymorphisms in type 2 diabetes and obesity risk in the Tunisian population. Clin Biochem. 2010;43(6):549–52.PubMedCrossRef
21.
Zurück zum Zitat Bouhaha R, et al. TCF7L2 is associated with type 2 diabetes in nonobese individuals from Tunisia. Pathol Biol (Paris). 2010;58(6):426–9.CrossRef Bouhaha R, et al. TCF7L2 is associated with type 2 diabetes in nonobese individuals from Tunisia. Pathol Biol (Paris). 2010;58(6):426–9.CrossRef
22.
Zurück zum Zitat Binns C, Low WY, Lee MK. Breast cancer: an increasing public health problem in the Asia pacific region. Asia Pac J Public Health. 2013;25(5):364–7.PubMedCrossRef Binns C, Low WY, Lee MK. Breast cancer: an increasing public health problem in the Asia pacific region. Asia Pac J Public Health. 2013;25(5):364–7.PubMedCrossRef
23.
Zurück zum Zitat Subramanian S, et al. MicroRNA expression signature of human sarcomas. Oncogene. 2008;27(14):2015–26.PubMedCrossRef Subramanian S, et al. MicroRNA expression signature of human sarcomas. Oncogene. 2008;27(14):2015–26.PubMedCrossRef
24.
Zurück zum Zitat Lin M, et al. MicroRNA expression profiles in human colorectal cancers with liver metastases. Oncol Rep. 2011;25(3):739–47.PubMedCrossRef Lin M, et al. MicroRNA expression profiles in human colorectal cancers with liver metastases. Oncol Rep. 2011;25(3):739–47.PubMedCrossRef
Metadaten
Titel
Wild-type genotypes of BRCA1 gene SNPs combined with micro-RNA over-expression in mammary tissue leading to familial breast cancer with an increased risk of distant metastases’ occurrence
verfasst von
Imen Medimegh
Wafa Troudi
Nejla Stambouli
Houssein Khodjet-El-Khil
Olfa Baroudi
Hajer Ayari
Ines Omrane
Nancy Uhrhammer
Maud Privat
Amel Mezlini
Farhat Ben Ayed
Khaled Ben Romdhane
Sylvie Mader
Yve Jean Bignon
Amel Benammar Elgaaied
Publikationsdatum
01.11.2014
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 11/2014
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0255-6

Weitere Artikel der Ausgabe 11/2014

Medical Oncology 11/2014 Zur Ausgabe

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.